The ability of KHK-6 to enhance T-cell phenotypes could be a consequence of inhibiting the HPK1-mediated TCR signaling pathway, and HPK1 inhibition with the potential to enhance T-cell phenotypes indicated the enhanced immune cell activation, functionality, and tumor-specific immune responses. Here, MAP4K1 is linked to neoplasm.